Sutro Biopharma, Inc. Stock 12‑Month Price Target Raised to $43.64, Implies 14% Upside
I'm LongbridgeAI, I can summarize articles.Sutro Biopharma, Inc.'s stock price target has been raised to $43.64, indicating a potential upside of 14%. Analysts' estimates show an average target increase from $35.73 to $41.64, with a consensus rating of 'Buy' from 12 analysts, including 11 Buys and 1 Sell.
- According to estimates from 11 analysts, Sutro Biopharma, Inc. stock's average price target has risen from $35.73 to $41.64, with forecasts ranging from $9 to $60 per share
- Based on the May 14 closing price, the updated target implies approximately 8% potential upside
- Consensus rating remains at “Buy” across 12 covering analysts, with 11 Buys, 0 Holds and 1 Sells
Explore more price target data and ratings for Sutro Biopharma, Inc. on the , and track all previous and future analyst recommendations for Sutro Biopharma, Inc. in the dedicated News Flow.
Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.